These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29659758)

  • 1. Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.
    Kevans D; Murthy S; Mould DR; Silverberg MS
    J Crohns Colitis; 2018 May; 12(6):662-669. PubMed ID: 29659758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.
    Moore H; Dolce P; Devas N; Baldassano R; Martinelli M
    United European Gastroenterol J; 2020 May; 8(4):425-435. PubMed ID: 32213038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
    Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
    Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous versus intravenous infliximab therapy - a real-world study: toward higher drug concentrations.
    Ferreira AI; Lima Capela T; Arieira C; Xavier S; Cotter J
    Eur J Gastroenterol Hepatol; 2024 Nov; 36(11):1314-1318. PubMed ID: 39166409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.
    Roblin X; Nancey S; Papamichael K; Duru G; Flamand M; Kwiatek S; Cheifetz A; Fabien N; Barrau M; Paul S
    J Crohns Colitis; 2024 May; 18(5):679-685. PubMed ID: 37934041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.
    Naviglio S; Lacorte D; Lucafò M; Cifù A; Favretto D; Cuzzoni E; Silvestri T; Pozzi Mucelli M; Radillo O; Decorti G; Fabris M; Bramuzzo M; Taddio A; Stocco G; Alvisi P; Ventura A; Martelossi S
    J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):37-44. PubMed ID: 30211845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling.
    Kimura K; Yoshida A; Katagiri F; Takayanagi R; Yamada Y
    Eur J Pharm Sci; 2020 Jul; 150():105317. PubMed ID: 32205229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis.
    Whaley KG; Xiong Y; Karns R; Hyams JS; Kugathasan S; Boyle BM; Walters TD; Kelsen J; LeLeiko N; Shapiro J; Waddell A; Fox S; Bezold R; Bruns S; Widing R; Haberman Y; Collins MH; Mizuno T; Minar P; D'Haens GR; Denson LA; Vinks AA; Rosen MJ
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1338-1347. PubMed ID: 36031093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
    Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D
    Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis.
    Murthy SK; Greenberg GR; Croitoru K; Nguyen GC; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2015 Sep; 21(9):2090-6. PubMed ID: 26099066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
    BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics.
    Colman RJ; Vuijk SA; Mathôt RAA; Van Limbergen J; Jongsma MME; Schreurs MWJ; Minar P; de Ridder L; D'Haens GRAM
    Inflamm Bowel Dis; 2024 Oct; 30(10):1678-1685. PubMed ID: 38167922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases.
    Nemoz B; Ternant D; Bailly S; Gautier-Veyret E; Jourdil JF; Bonaz B; Stanke-Labesque F
    Br J Clin Pharmacol; 2019 Apr; 85(4):722-728. PubMed ID: 30575085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    J Crohns Colitis; 2018 Nov; 12(11):1316-1325. PubMed ID: 30239644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
    Kobayashi T; Suzuki Y; Motoya S; Hirai F; Ogata H; Ito H; Sato N; Ozaki K; Watanabe M; Hibi T
    J Gastroenterol; 2016 Mar; 51(3):241-51. PubMed ID: 26162647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.